From Product to Global Profitability in Horses

We follow our “roadmap to EMA & USDA (FDA) approval”, are prepared for global launches in 3-4 years. We presented at leading CEO & investor conferences in 2025 attracting interest and resonance by investors

Dual mechanism of action, vaccination and intra cellular stimulation, targeted cell death

Impressive CR/R and “cure” results

CMC and pivotal studies (II-III) “good to go”

Focus on clinical & pre-commercialisation in very few years (“hand in hand”, globally)

“When the strategy is clear, execution becomes the strategy”

P. Drucker (1965)

Our product is now entering clinical confirmation studies and will reach markets in 3-4 years as to plans. More than 78+ horses were successfully treated on sarcoids (skin cancers) including most severe cases in late stage (pre-metastatic bone disease). Our pivotal trials need “some more” actively treated horses and 1/3 of placebos (“nothing more”)

As part of EDC companies, we were selected for our honest approach and developed by NEMOO AI Value Builders EDC AG. Our business plans are our financial investment plans. They are identical, externally, internally. We provide measurements at least 6-monthly, ad hoc to investors (in line with US-GAAP). We benefit from NEMOO AI EDCs support, experience, coaching, structures and network. We drive valuation, develop projects, people, teams, in a lean way with simple AI solutions – together. We also sit together for future options and expansion, opportunities arising. We hence, are learning & expand together

Our team is solid, well educated, science & ethics driven, R&D focused, strong in global commercial and finance (M&A, costs)

We partner with investors closely to create optimal value, developments and/or exits together

From Product to Profitability

Our ANNIMOO Core Team consists of various people, experiences, backgrounds, operational track records in commercialisation and drug development (PAREXEL), manufacturing (LONZA), biotech and pharma (Roche, Novartis, AstraZeneca, Biogen, Roche Diagnostics), scientific and clinical development (BlueSky, Cubist, PAREXEL), rare diseases (SOBI), regulatory and finance (PAREXEL, LONZA, Roche, SP / Merck & Co.) & IO immunology / biotechnology (GreenHills, BlueSky, SOBI)

Advisor IA
(ex SP/MSD,
Switzerland, USA)
Advisor IA
(ex Amgen IP & Legal
Head EMEA, Switzerland)
Advisor IA
(Prof. of Kellogg MBA, Germany, Sweden)
Advisor IA
(ex MSD, Novartis, Swiss Investment Banking)

We are posting updates and relevant news from time to time on the development and science of our products in horses and camels

Thank you for your interest

Christian & Claudia